MA50383A - Agents thérapeutiques pour maladies neurodégénératives - Google Patents

Agents thérapeutiques pour maladies neurodégénératives

Info

Publication number
MA50383A
MA50383A MA050383A MA50383A MA50383A MA 50383 A MA50383 A MA 50383A MA 050383 A MA050383 A MA 050383A MA 50383 A MA50383 A MA 50383A MA 50383 A MA50383 A MA 50383A
Authority
MA
Morocco
Prior art keywords
therapeutic agents
neurodegenerative diseases
neurodegenerative
diseases
therapeutic
Prior art date
Application number
MA050383A
Other languages
English (en)
Other versions
MA50383B1 (fr
Inventor
Mallory Factor
Original Assignee
Intrabio Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intrabio Ltd filed Critical Intrabio Ltd
Publication of MA50383A publication Critical patent/MA50383A/fr
Publication of MA50383B1 publication Critical patent/MA50383B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia

Landscapes

  • Health & Medical Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Medicinal Preparation (AREA)
MA50383A 2017-10-18 2018-02-15 Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos MA50383B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201762574137P 2017-10-18 2017-10-18
PCT/US2018/018420 WO2019078915A1 (fr) 2017-10-18 2018-02-15 Agents thérapeutiques pour maladies neurodégénératives
EP18708286.2A EP3697399B1 (fr) 2017-10-18 2018-02-15 Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos

Publications (2)

Publication Number Publication Date
MA50383A true MA50383A (fr) 2020-08-26
MA50383B1 MA50383B1 (fr) 2026-01-30

Family

ID=66174216

Family Applications (1)

Application Number Title Priority Date Filing Date
MA50383A MA50383B1 (fr) 2017-10-18 2018-02-15 Agents thérapeutiques pour l'utilisation dans le traitement du syndrome des jambes sans repos

Country Status (24)

Country Link
US (1) US11793782B2 (fr)
EP (2) EP3697399B1 (fr)
JP (1) JP2021500342A (fr)
KR (1) KR102549684B1 (fr)
CN (1) CN111542314B (fr)
AU (1) AU2018351709B2 (fr)
CA (1) CA3079194A1 (fr)
DK (1) DK3697399T3 (fr)
ES (1) ES3057584T3 (fr)
FI (1) FI3697399T3 (fr)
HR (1) HRP20251695T1 (fr)
IL (1) IL273929B2 (fr)
LT (1) LT3697399T (fr)
MA (1) MA50383B1 (fr)
MD (1) MD3697399T2 (fr)
MX (1) MX2020003427A (fr)
PL (1) PL3697399T3 (fr)
PT (1) PT3697399T (fr)
RS (1) RS67601B1 (fr)
RU (1) RU2763425C2 (fr)
SG (1) SG11202003390UA (fr)
SI (1) SI3697399T1 (fr)
SM (1) SMT202500483T1 (fr)
WO (1) WO2019078915A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201709459D0 (en) 2017-06-14 2017-07-26 Intrabio Ltd Treatment for migraine
IL276576B2 (en) * 2018-02-15 2024-10-01 Intrabio Ltd Therapeutic agents for treating restless legs syndrome
WO2025163129A1 (fr) * 2024-02-01 2025-08-07 Intrabio Ltd. Acétylleucine pour le traitement de la maladie de parkinson
US12403111B2 (en) 2024-02-02 2025-09-02 SynGAP Research Fund Compositions and methods for treating neurodevelopmental disorders

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2006519875A (ja) * 2003-03-06 2006-08-31 セルジーン・コーポレーション 中枢神経系障害を治療するための選択的サイトカイン阻害剤
RU2377234C2 (ru) * 2003-09-17 2009-12-27 Ксенопорт, Инк. Лечение или предупреждение синдрома беспокойных ног с использованием пролекарств аналогов гамк
WO2008140449A1 (fr) * 2007-05-11 2008-11-20 Thomas Jefferson University Méthodes de traitement et de prévention de maladies et de troubles neurodégénératifs
EP2289886A1 (fr) * 2009-08-31 2011-03-02 Institut d'Investigacions Biomédiques August PI I Sunyer Peptoides agonistes du facteur de croissance nerveuse et leur utilisation en tant que médicaments
US8202525B2 (en) * 2009-12-22 2012-06-19 Pondera Biotechnologies, LLC Methods and compositions for treating distress dysfunction and enhancing safety and efficacy of specific medications
TN2010000251A1 (fr) * 2010-06-03 2011-11-11 Rekik Raouf N-acetyl-dl-leucine medicament neuro et retino protecteur
WO2011163648A1 (fr) 2010-06-25 2011-12-29 Shire Human Genetic Therapies, Inc. Administration au snc d'agents thérapeutiques
MX2016011152A (es) * 2014-02-27 2016-12-09 Medrx Co Ltd Parche transdermico que contiene pramipexol para tratamiento de enfermedad neurodegenerativa.
DE102016000393A1 (de) 2015-10-01 2017-04-06 Linde Aktiengesellschaft Verfahren zum Verflüssigen einer Kohlenwasserstoff-reichen Fraktion
IL310801A (en) * 2016-08-11 2024-04-01 Intrabio Ltd Acetyl-leucine for use in treating neurodegenerative diseases

Also Published As

Publication number Publication date
JP2021500342A (ja) 2021-01-07
BR112020007657A2 (pt) 2020-09-29
KR102549684B1 (ko) 2023-06-29
WO2019078915A1 (fr) 2019-04-25
EP3697399A1 (fr) 2020-08-26
MA50383B1 (fr) 2026-01-30
RU2020115710A (ru) 2021-11-18
CA3079194A1 (fr) 2019-04-25
IL273929B2 (en) 2024-11-01
IL273929A (en) 2020-05-31
US11793782B2 (en) 2023-10-24
EP3697399B1 (fr) 2025-11-26
CN111542314B (zh) 2023-11-24
EP4467138A2 (fr) 2024-11-27
SMT202500483T1 (it) 2026-01-12
RU2020115710A3 (fr) 2021-11-18
FI3697399T3 (fi) 2026-01-08
SG11202003390UA (en) 2020-05-28
AU2018351709A1 (en) 2020-05-07
EP4467138A3 (fr) 2025-02-26
DK3697399T3 (da) 2025-12-22
MX2020003427A (es) 2020-09-14
US20210196659A1 (en) 2021-07-01
SI3697399T1 (sl) 2026-02-27
IL273929B1 (en) 2024-07-01
HRP20251695T1 (hr) 2026-02-27
RU2763425C2 (ru) 2021-12-29
LT3697399T (lt) 2026-01-12
PT3697399T (pt) 2025-12-24
RS67601B1 (sr) 2026-01-30
MD3697399T2 (ro) 2026-02-28
AU2018351709B2 (en) 2024-01-04
CN111542314A (zh) 2020-08-14
ES3057584T3 (en) 2026-03-03
KR20200074170A (ko) 2020-06-24
PL3697399T3 (pl) 2026-03-23

Similar Documents

Publication Publication Date Title
MA47521A (fr) Agents thérapeutiques pour maladies neurodégénératives
GB201820166D0 (en) Therapeutic agents
GB201820165D0 (en) Therapeutic agents
IL270916A (en) Combined therapy for nmdar antagonist-responsive neuropsychiatric disorders
MA48996A (fr) Méthodes de traitement de maladies neurodégénératives
MA53568A (fr) Médicaments pour le traitement de maladies ophtalmiques
EP3735463A4 (fr) Agent thérapeutique induisant une cytotoxicité
EP3316887A4 (fr) Inhibiteurs de gls1 pour le traitement de maladies
IL281869B1 (en) Medical cause for degenerative nerve disease
GB201805816D0 (en) Therapeutic agents
IL273929A (en) Therapeutic agents for neurodegenerative diseases
EP3371210A4 (fr) Polythérapie pour maladies malignes
EP3634394A4 (fr) Compositions pour le traitement de maladies neurodégénératives
EP3828546A4 (fr) Composition pour diagnostiquer des maladies
GB201700553D0 (en) Therapeutic agents
EP2949329A4 (fr) Agent thérapeutique pour maladies démyélinisantes
MA54630A (fr) N,n-bis-2-mercaptoéthyle isophtalamide pour le traitment des maladies neurodégénératives
EP3846816A4 (fr) Agents neuroprotecteurs pour le traitement de maladies neurodégénératives
EP3903882A4 (fr) Agent thérapeutique pour bradyarhytmie héréditaire
EP3508214A4 (fr) Agent thérapeutique pour maladies ischémiques.
EP3731854A4 (fr) Agents thérapeutiques de protéines de fusion ptd-smad7
EP3399999A4 (fr) Thérapeutique pour maladies immuno-inflammatoires oculaires
EP3539561A4 (fr) Agent thérapeutique pour infarctus cérébral
GB201820168D0 (en) Therapeutic agents
GB201820170D0 (en) Therapeutic agents